Ivermectin is a widely distributed veterinary drug and for some decades it has been authorized to combat parasites in humans, even some of its formulas are sold in pharmacies.
Now, research trying to demonstrate the efficacy of Ivermectin in the prevention and treatment of COVID-19 has produced its first results.
According to the study that was published in the scientific journal E Clinical Medicine, of the editorial group The Lancet, Ivermectin has shown a potent activity against SARS-CoV-2.
The potential role of this antiparasitic against COVID-19 was first reported in April 2020, when a group of Australian researchers published the first results.
The last study aimed to evaluate the antiviral effect of ivermectin on the viral load of respiratory secretions and its relationship with the plasma concentrations of the drug.
It was a test to evaluate the antiviral activity of Ivermectin in high doses in 45 hospitalized patients with COVID-19.
In trials, dosing of the antiparasitic was shown to reduce the viral concentration in patients.
According to those in charge, in the first four months of trials it was found that the administration of this drug, at a dose of 0.6 milligrams per kilo of weight, produces “the fastest and deepest elimination of the virus when treatment is started in stages. early infection (up to 5 days from the onset of symptoms) ”.
For now, the World Health Organization recommends that the drug Ivermectin only be administered within clinical trials on COVID-19 until there is more evidence.